Picture: Julia Teichmann/Pixabay

The medical cannabis market has grown significantly in recent years. In Germany, the quantity of imported cannabis products has increased dramatically. In comparison to only 1.2 tons in 2017, German medical cannabis distributors imported about 3.13 metric tons of cannabis flowers for direct medical care of patients in 2018, while around 120 kg have been re-exported. In 2019, this amount doubled to around 6.7 tons.

Nick Moore now supports Scottish BioAscent Discovery Ltd. in further developing its business in North America.

© Kevin Schneider/Pixabay.com

BioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m.    

One Projects Ltd is developing next generation AI driven devices to treat cardiac arrhythmia. © One Projects Ltd

OneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.

flag-1192625_1920.jpg

Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.

Schlieren-based proteomics specialist Biognosys AG announces the appointment of Dr Patrick Vink as Chairman of the board.

The vaccine is based on MHC class II Invariant chain molecule fused to a hepatitis C virus (HCV) antigen and encoded in an adenoviral vector. When injected into volunteers, we saw that the vaccination was able to induce HCV specific CD4+ T cells and a high proportion of HCV specific CD8+ T cells with an increased expression of activation and cytolytic markers.
© Ilaria Esposito, biorender.com

Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.

© NIAID

A clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients.

Curevac has developed a vaccine printer which has a high production capacity. © CureVac AG

In the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.

David Loew, formerly executive vice president of Sanofi Pasteur, was appointed as CEO of French Ipsen Pharma SA at the beginning of July.